Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the present study was to evaluate the effect of a 6-weeks treatment of a CE-marked combination oral formulation of hyaluronic acid with chondroitin sulphate and aluminium hydroxide (GERDOFF®), in addition to proton pump inhibitors (PPI) at the standard dose, versus PPI only, in patients with first diagnosed clinical presentation of extra-esophageal GERD symptoms.
The investigators verified the reduction of symptoms frequency, using a Likert questionnaire, and severity, using the Reflux Symptom Index (RSI) questionnaire, to evaluate the proportion of Responders and Non-Responder patients in these two groups after 6 weeks of treatment, compared to baseline. Moreover investigators evaluated the persistence of effects of GERDOFF® + PPI treatment on extraesophageal symptoms, after a 12-weeks follow up, only in responder patients.
Cough, hoarseness, prolonged voice lowering, and vocal timbre modification, without any documentable cause, are considered as minor disorders for which patients do not receive adequate attention. These disorders may represent extra-esophageal manifestations of gastro-oesophagea reflux. Accurate diagnosis and gastro-oesophageal reflux therapy have been proved as useful to improve patients' quality of life.
The aim of the present study was to evaluate, in first diagnosed patients presenting with upper symptoms associated with GERD, the effect of a 6-week treatment with a combination based on CS, HA and aluminium hydroxide (Gerdoff®), co-administered with a treatment with PPIs, compared to treatment with PPIs as monotherapy, i.e. to verify, in patients treated with the combination of the two products, the reduction in symptoms frequency by means of a Likert questionnaire and the severity of upper symptoms by means of the Reflux Symptom Index (RSI) questionnaire, and to collect safety data. After 6 weeks of treatment, patients included in the two groups were then classified as responders or non-responders. Responder patients were defined as those patients that, at the 6th week of treatment, reached a RSI score decreased for at least 50% compared to baseline and an absolute value < 13.
Furthermore, the maintenance of the effect of treatment on the extra-oesophageal symptoms was evaluated after a period of follow-up lasting 12 weeks, which could be entered only by responder patients randomised in the Gerdoff®-PPI arm. Patients included in the follow-up period were randomised to receive Gerdoff® or no treatment (control group). Safety data were also evaluated in the group of patients that continued in the follow-up period.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GERDOFF® + omeprazole | Experimental | GERDOFF® (tablets) was orally administered 3 times per day after meals; omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days). Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days). |
|
| Omeprazole | Active Comparator | Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GERDOFF® + Omeprazole | Device | GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg + Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days). |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline to Visit V4 of the Total Score of RSI Questionnaire | After 6 weeks of treatment, the changes from baseline in the score of Reflux Symptom Index questionnaire were evaluated to verify the effects of treatments on high symptoms. The RSI questionnaire examines 9 items that are scored from 0 to 5, with a higher score that indicates a higher severity of the symptom (range of total score: 0-45). | In the first visit (baseline) and in the visit 4 (after 6 weeks of treatment) |
| Measure | Description | Time Frame |
|---|---|---|
| Total Score of Reflux Symptom Index Questionnaire in All Time-points Assessed | Total score of the Reflux Symptom Index questionnaire assessed in all time-points. The RSI questionnaire examines 9 items, that are scored from 0 to 5, with a higher score that indicates a higher severity of the symptom (range of total score: 0-45). | In baseline Visit, Visit 2 (after 1 week), Visit 3 (after 3 weeks) and Visit 4 (after 6 weeks of treatment) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alessandro Repici, MD | Istituto Clinico Humanitas | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| dr Alessandro Repici | Rozzano | MI | 20089 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
In this phase of the study, 72 patients were enrolled. One patient withdrew the informed consent and was excluded from the study before randomization.
A first specialist visit was performed by an ENT as per clinical practice based on patient's symptoms.
Patients sent by the ENT should not have been pre-treated with PPIs and/or medical devices and/or similar products. The diagnosis was confirmed by the Gastroenterologist Investigator who recruited patients.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | GERDOFF® + Omeprazole | GERDOFF® (tablets) was orally administered 3 times per day after meals; omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days). GERDOFF®: GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg |
| FG001 | Omeprazole | Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days). Omeprazole: Omeprazole, 2 capsules 20 mg, once a day before breakfast |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | GERDOFF® + Omeprazole | GERDOFF® (tablets) was orally administered 3 times per day after meals; omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days). GERDOFF®: GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg |
| BG001 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline to Visit V4 of the Total Score of RSI Questionnaire | After 6 weeks of treatment, the changes from baseline in the score of Reflux Symptom Index questionnaire were evaluated to verify the effects of treatments on high symptoms. The RSI questionnaire examines 9 items that are scored from 0 to 5, with a higher score that indicates a higher severity of the symptom (range of total score: 0-45). | Four patients in the GERFOFF + omeprazole group did not complete the Reflux Symptom Index questionnaire and could not be included in the analysis. | Posted | Mean | Standard Deviation | Score on a scale | In the first visit (baseline) and in the visit 4 (after 6 weeks of treatment) |
|
During the 6 weeks of treatment in non-responders in the group GERDOFF+PPI and in patients randomized in PPI group; during the 6 weeks of treatment and 12-week follow-up in responder patients randomized in the group GERDOFF + PPI
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | GERDOFF® + Omeprazole | GERDOFF® (tablets) was orally administered 3 times per day after meals; omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days). GERDOFF®: GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Atrial fibrillation | Cardiac disorders | MedDRA (20.1) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Migraine | Nervous system disorders | MedDRA (20.1) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr Francesca Baldan | Sofar Spa | 0039 02 909362 | 1 | francesca.baldan@sofarfarm.it |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Feb 20, 2017 | Jan 25, 2020 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D005764 | Gastroesophageal Reflux |
| ID | Term |
|---|---|
| D015154 | Esophageal Motility Disorders |
| D003680 | Deglutition Disorders |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D009853 | Omeprazole |
| ID | Term |
|---|---|
| D053799 | 2-Pyridinylmethylsulfinylbenzimidazoles |
| D013454 | Sulfoxides |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
Not provided
Not provided
Patients was randomized in an open-label treatment (in a ratio 1:1) and treated with the investigational medical device (IMD) + proton pump inhibitor (PPI) or PPI only for 6 weeks. At the end of treatment visit (V4) only patients who were classified as responders and belonging to the GERDOFF®+PPI group were included in the follow-up phase for 12 further weeks. During the follow-up, patients were randomized to an open-label treatment (in a 1:1 ratio) to GERDOFF® group or control group that will not receive any treatment for 12 weeks in order to evaluate the maintenance of treatment effects. To safeguard the health and well-being of patients, and to keep under control the possible upper symptoms of GERD that could appear, all patients that continued in the follow-up period received omeprazole as rescue medication, in a quantity adequate to cover the entire follow-up period.
Not provided
Not provided
Not provided
Not provided
|
| Omeprazole | Drug | Omeprazole, 2 capsules 20 mg, once a day before breakfast |
|
|
| Score of Hoarseness or Vocal Problem of the RSI Questionnaire Measured at the Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including hoarseness or vocal problem that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | At baseline and in the visit 4, after 6 weeks of treatment |
| Score of Throat of the RSI Questionnarie Measured at the Baseline and in the Visit 4 of the RSI Questionnaire Score of Throat Clearance | The Reflux Symptom Index questionnaire examines 9 items, including throat that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | At baseline and in the visit 4, after 6 weeks of treatment |
| Score of Excess of Mucus in the Throat or Retrosternal Fall of Secretions of the RSI Questionnaire Measured at Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including excess of mucus in the throat or retrosternal fall of secretions that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | At baseline and in the visit 4, after 6 weeks of treatment |
| Score of Difficulty in Swallowing Food, Fluids or Pills of the RSI Questionnaire Measured at Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including difficulty in swallowing food, fluids or pills that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | At baseline and in the visit 4, after 6 weeks of treatment |
| Score of Cough of the RSI Questionnaire Measured at Baseline and in the Visit 4 After the Meal or After Lying | The Reflux Symptom Index questionnaire examines 9 items, including cough that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | At baseline and in the visit 4, after 6 weeks of treatment |
| Score of Difficulty in Breathing or Episodes of Choking of the RSI Questionnaire Measured at Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including difficulty in breathing or episodes of choking that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | At baseline and in the visit 4, after 6 weeks of treatment |
| Score of Problematic or Troublesome Cough of the RSI Questionnaire Measured at Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including problematic or troublesome cough that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | At baseline and in the visit 4, after 6 weeks of treatment |
| Score of Sensation of Something Blocked or Mass in the Throat of the RSI Questionnaire Measured at Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including sensation of something blocked or mass in the throat that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | At baseline and in the visit 4, after 6 weeks of treatment |
| Score of Stomach Burning, Thoracic Pain, Poor Digestion of Gastric Acid That Moves Upright of the RSI Questionnaire Measured at Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including stomach burning, thoracic pain, poor digestion of gastric acid that moves upright that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | At baseline and in the visit 4, after 6 weeks of treatment |
| Number of Responders V4 | A responder was defined as a patient who at the 6th week of treatment showed a reduction of at least 50% vs. the baseline and an absolute value < 13 on the RSI questionnaire. | At visit 4 after 6 weeks of treatment |
| Number of Responders V6 | Responder patients of Group Gerdoff® + omeprazole were randomly assigned to receive a treatment with Gerdoff®-one tablet three times daily- All patients received a packaging of omeprazole, to be taken only if necessary, at constant dose and according to the indications of the Investigator. The scheduled duration of the follow-up period was 12 weeks. A responder was defined as a patient who at the 6th week of treatment showed a reduction of at least 50% vs. the baseline and an absolute value < 13 on the RSI questionnaire. | In the Visit 6 at the end of follow-up |
| Score of Upper Symptoms Using the Likert Scale at Baseline and in the Visit V4 | The Likert scale examines 9 symptoms, to be scored from 0 to 4, with a higher score indication a higher frequency of the symptom (i.e. 0=never, 1=occasionally, 2=sometimes, 3= often, 4=Always); The Likert scale scores of single items are as following:
Subscales are summarized to compute a total score (total score ranges from 0-36). The mean values of Likert scale total score are reported. | At baseline and in the visit 4 |
| Presence of Upper Symptoms at Visit 4, Using the RSI Questionnaire | The Reflux Symptom Index questionnaire examines 9 items, to be scored from 0 to 5, with a higher score indication a higher severity of the symptom (range of total score: 0-45). | At visit 4 after weeks of treatment |
| Use of Rescue Medication (Omeprazole) During the Treatment | In the first 6 weeks of treatment, the intake in each treatment group of the rescue medication, allowed or not allowed, was calculated as the frequency of intake of the specific drug and the comparison between groups was performed using the Fisher's exact test. | From baseline to visit 4 |
| Use of Rescue Medication (Omeprazole) During the Follow-up | During the follow-up, the intake in each treatment group of the rescue medication, allowed or not allowed, was calculated as the frequency of intake of the specific drug. | In the Visit 6 after 12 weeks from baseline |
| Use of Rescue Medication (Other Than Omeprazole) During Treatment | During treatment, the intake in each treatment group of the rescue medication, allowed or not allowed, was calculated as the frequency of intake of the specific drug. | From baseline to visit 4 |
| Patients'Satisfaction | This evaluation was expressed with a semi-quantitative ordinal scale: 0 = low, 1 = discrete, 2 = good, 3 = excellent). | At visit 4 after weeks of treatment |
| Omeprazole |
Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days). Omeprazole: Omeprazole, 2 capsules 20 mg, once a day before breakfast |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Patients with simultaneous symptoms | Number | participants |
|
| Hoarseness or vocal problem | Number | participants |
|
| Throat clearance | Number | participants |
|
| Excess of mucus in the throat or retrosternal fall of secretions | Number | participants |
|
| Difficulty in swallowing food, fluids or pills | Number | participants |
|
| Cough after the meal or after lying | Number | participants |
|
| Difficulty in breathing or episodes of choking | Number | participants |
|
| Problematic or troublesome cough | Number | participants |
|
| Sensation of something blocked or mass in the throat | Number | participants |
|
| Stomach burning, thoracic pain, poor digestion of gastric acid that moves upright | Number | participants |
|
| Weight | Some data are missing in both arms | Median | Full Range | kg |
|
| Body Mass Index | Some data are missing in both arms | Median | Full Range | kg/m^2 |
|
| Number of symptoms | Median | Full Range | Symptom |
|
| OG001 | Omeprazole | Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days). Omeprazole: Omeprazole, 2 capsules 20 mg, once a day before breakfast |
|
|
|
| Secondary | Total Score of Reflux Symptom Index Questionnaire in All Time-points Assessed | Total score of the Reflux Symptom Index questionnaire assessed in all time-points. The RSI questionnaire examines 9 items, that are scored from 0 to 5, with a higher score that indicates a higher severity of the symptom (range of total score: 0-45). | Some data are missing; therefore, the number of participants in one or more rows differs from overall number analyzed. | Posted | Mean | Standard Deviation | score on a scale | In baseline Visit, Visit 2 (after 1 week), Visit 3 (after 3 weeks) and Visit 4 (after 6 weeks of treatment) |
|
|
|
|
| Secondary | Score of Hoarseness or Vocal Problem of the RSI Questionnaire Measured at the Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including hoarseness or vocal problem that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | Posted | Mean | Standard Deviation | score on a scale | At baseline and in the visit 4, after 6 weeks of treatment |
|
|
|
| Secondary | Score of Throat of the RSI Questionnarie Measured at the Baseline and in the Visit 4 of the RSI Questionnaire Score of Throat Clearance | The Reflux Symptom Index questionnaire examines 9 items, including throat that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | Posted | Mean | Standard Deviation | score on a scale | At baseline and in the visit 4, after 6 weeks of treatment |
|
|
|
| Secondary | Score of Excess of Mucus in the Throat or Retrosternal Fall of Secretions of the RSI Questionnaire Measured at Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including excess of mucus in the throat or retrosternal fall of secretions that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | Posted | Mean | Standard Deviation | score on a scale | At baseline and in the visit 4, after 6 weeks of treatment |
|
|
|
| Secondary | Score of Difficulty in Swallowing Food, Fluids or Pills of the RSI Questionnaire Measured at Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including difficulty in swallowing food, fluids or pills that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | Posted | Mean | Standard Deviation | score on a scale | At baseline and in the visit 4, after 6 weeks of treatment |
|
|
|
| Secondary | Score of Cough of the RSI Questionnaire Measured at Baseline and in the Visit 4 After the Meal or After Lying | The Reflux Symptom Index questionnaire examines 9 items, including cough that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | Posted | Mean | Standard Deviation | score on a scale | At baseline and in the visit 4, after 6 weeks of treatment |
|
|
|
| Secondary | Score of Difficulty in Breathing or Episodes of Choking of the RSI Questionnaire Measured at Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including difficulty in breathing or episodes of choking that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | Posted | Mean | Standard Deviation | score on a scale | At baseline and in the visit 4, after 6 weeks of treatment |
|
|
|
| Secondary | Score of Problematic or Troublesome Cough of the RSI Questionnaire Measured at Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including problematic or troublesome cough that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | Posted | Mean | Standard Deviation | score on a scale | At baseline and in the visit 4, after 6 weeks of treatment |
|
|
|
| Secondary | Score of Sensation of Something Blocked or Mass in the Throat of the RSI Questionnaire Measured at Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including sensation of something blocked or mass in the throat that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | Posted | Mean | Standard Deviation | score on a scale | At baseline and in the visit 4, after 6 weeks of treatment |
|
|
|
| Secondary | Score of Stomach Burning, Thoracic Pain, Poor Digestion of Gastric Acid That Moves Upright of the RSI Questionnaire Measured at Baseline and in the Visit 4 | The Reflux Symptom Index questionnaire examines 9 items, including stomach burning, thoracic pain, poor digestion of gastric acid that moves upright that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom. | Posted | Mean | Standard Deviation | Score on a scale | At baseline and in the visit 4, after 6 weeks of treatment |
|
|
|
| Secondary | Number of Responders V4 | A responder was defined as a patient who at the 6th week of treatment showed a reduction of at least 50% vs. the baseline and an absolute value < 13 on the RSI questionnaire. | Posted | Count of Participants | Participants | At visit 4 after 6 weeks of treatment |
|
|
|
|
| Secondary | Number of Responders V6 | Responder patients of Group Gerdoff® + omeprazole were randomly assigned to receive a treatment with Gerdoff®-one tablet three times daily- All patients received a packaging of omeprazole, to be taken only if necessary, at constant dose and according to the indications of the Investigator. The scheduled duration of the follow-up period was 12 weeks. A responder was defined as a patient who at the 6th week of treatment showed a reduction of at least 50% vs. the baseline and an absolute value < 13 on the RSI questionnaire. | Posted | Count of Participants | Participants | In the Visit 6 at the end of follow-up |
|
|
|
| Secondary | Score of Upper Symptoms Using the Likert Scale at Baseline and in the Visit V4 | The Likert scale examines 9 symptoms, to be scored from 0 to 4, with a higher score indication a higher frequency of the symptom (i.e. 0=never, 1=occasionally, 2=sometimes, 3= often, 4=Always); The Likert scale scores of single items are as following:
Subscales are summarized to compute a total score (total score ranges from 0-36). The mean values of Likert scale total score are reported. | Posted | Mean | Standard Deviation | Score on a scale | At baseline and in the visit 4 |
|
|
|
|
| Secondary | Presence of Upper Symptoms at Visit 4, Using the RSI Questionnaire | The Reflux Symptom Index questionnaire examines 9 items, to be scored from 0 to 5, with a higher score indication a higher severity of the symptom (range of total score: 0-45). | Posted | Count of Participants | Participants | At visit 4 after weeks of treatment |
|
|
|
| Secondary | Use of Rescue Medication (Omeprazole) During the Treatment | In the first 6 weeks of treatment, the intake in each treatment group of the rescue medication, allowed or not allowed, was calculated as the frequency of intake of the specific drug and the comparison between groups was performed using the Fisher's exact test. | Posted | Count of Participants | Participants | From baseline to visit 4 |
|
|
|
| Secondary | Use of Rescue Medication (Omeprazole) During the Follow-up | During the follow-up, the intake in each treatment group of the rescue medication, allowed or not allowed, was calculated as the frequency of intake of the specific drug. | Posted | Count of Participants | Participants | In the Visit 6 after 12 weeks from baseline |
|
|
|
| Secondary | Use of Rescue Medication (Other Than Omeprazole) During Treatment | During treatment, the intake in each treatment group of the rescue medication, allowed or not allowed, was calculated as the frequency of intake of the specific drug. | Posted | Count of Participants | Participants | From baseline to visit 4 |
|
|
|
| Secondary | Patients'Satisfaction | This evaluation was expressed with a semi-quantitative ordinal scale: 0 = low, 1 = discrete, 2 = good, 3 = excellent). | Four patients in the GERFOFF + omeprazole group did not complete the Reflux Symptom Index questionnaire and could not be included in the analysis. | Posted | Count of Participants | Participants | At visit 4 after weeks of treatment |
|
|
|
| 0 |
| 35 |
| 0 |
| 35 |
| 14 |
| 35 |
| EG001 | Omeprazole | Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days). Omeprazole: Omeprazole, 2 capsules 20 mg, once a day before breakfast | 0 | 36 | 1 | 36 | 12 | 36 |
| Flu-like symptoms | General disorders | MedDRA (20.1) | Systematic Assessment |
|
| Pyrexia | General disorders | MedDRA (20.1) | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | MedDRA (20.1) | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA (20.1) | Systematic Assessment |
|
| Red blood cell sedimentation rate increased | Investigations | MedDRA (20.1) | Systematic Assessment |
|
| C-reactive protein increased subjects affected / exposed | Investigations | MedDRA (20.1) | Systematic Assessment |
|
| Tachycardia | Cardiac disorders | MedDRA (20.1) | Systematic Assessment |
|
| Hypersensitivity | Immune system disorders | MedDRA (20.1) | Systematic Assessment |
|
| Bronchospasm | Respiratory, thoracic and mediastinal disorders | MedDRA (20.1) | Systematic Assessment |
|
| Clonus | Nervous system disorders | MedDRA (20.1) | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA (20.1) | Systematic Assessment |
|
| Chills | General disorders | MedDRA (20.1) | Systematic Assessment |
|
| Anxiety | Psychiatric disorders | MedDRA (20.1) | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA (20.1) | Systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | MedDRA (20.1) | Systematic Assessment |
|
| Dysentery | Gastrointestinal disorders | MedDRA (20.1) | Systematic Assessment |
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA (20.1) | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA (20.1) | Systematic Assessment |
|
| Hypertransaminasaemia | Hepatobiliary disorders | MedDRA (20.1) | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (20.1) | Systematic Assessment |
|
| neck pain | Musculoskeletal and connective tissue disorders | MedDRA (20.1) | Systematic Assessment |
|
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA (20.1) | Systematic Assessment |
|
| Gastroenteritis | Infections and infestations | MedDRA (20.1) | Systematic Assessment |
|
| Infection | Infections and infestations | MedDRA (20.1) | Systematic Assessment |
|
| Sinusitis | Infections and infestations | MedDRA (20.1) | Systematic Assessment |
|
Not provided
Not provided
| D004066 | Digestive System Diseases |
| D011725 |
| Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Visit 2 |
|
|
| Visit 3 |
|
|
| Visit 4 |
|
|
| 2 symptoms |
|
| 3 symptoms |
|
| 4 symptoms |
|
| 5 symptoms |
|
| 6 symptoms |
|
| Discrete |
|
| Good |
|
| Excellent |
|